the purpose of this project is the investigation of lhrha2 integrated effect with carp pituitary extract (cpe) in three stages injection on sexual indexes (fecundity, fertilization, hatch and larval survival) in artificial propagation of barbusxanthopterus. 20 fish were divided in to 4 treatment and injected interpritoneal as follows 4mgkg-1b.w.of cpe as positive control, 4 µg/kg +4 mgkg-1b.w. ...

We treated ten men and ten women suffering from hypogonadotropic hypogonadism with LHRH. Our method of treatment differed 'from others in that a mini pump was not available at the onset of the study. Nine women were given injections via a heparinized indwelling catheter every 120 minutes for 14 days, i,e. the proliferative phase. After ovulation, 3000 IU human chorionic gonadotropin (HCG) ...

Endogenous opioids participate in the regulation of gonadotropin secretion through an influence on the release of the hypothalamic LHRH. However, it is not clear whether opioids exert a direct effect on LHRH-producing neurons or interfere with other systems able to influence LHRH release. A neuronal LHRH-producing cell line (GT1) developed recently provides a good model to study the mechanisms ...

DESCRIPTION TRELSTAR  DEPOT contains a pamoate salt of triptorelin, and triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH or GnRH) with greater potency than the naturally occurring LHRH. The chemical name of triptorelin pamoate is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-serylL-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycine amide (pam...

OBJECTIVE To report a case of right posterior subcapsular cataract induced by 3-monthly depot luteinizing hormone-releasing hormone (LHRH) analogue therapy in a patient with early prostate cancer. CASE PRESENTATION A 52-year-old male with static myopia of several years' duration was given a 3-month depot LHRH analogue (goserelin 10.8 mg) as part of neoadjuvant treatment for early prostate can...

Several abstracts presented at the 2015 European Association of Urology Meeting highlighted new developments in hormone therapy for prostate cancer management. One abstract described how the luteinizing hormone-releasing hormone (LHRH)/gonadotropin-releasing hormone (GnRH) agonist leuprolide, but not the LHRH/GnRH antagonist degarelix, induced plaque instability in a mouse model. A second abstr...

Although castration levels of serum androgens are consistently achieved after 2-3 weeks of treatment with luteinizing hormone-releasing hormone (LHRH) agonists, the administration of these peptides alone in adult men is always accompanied by a transient increase in plasma testosterone and dihydrotestosterone levels, which lasts for 5-15 days at the beginning of treatment and is accompanied by d...

The ferret is a reflexively ovulating species in which mating induces a preovulatory LH surge in the estrous female but significantly decreases LH secretion in the breeding male. This sexually dimorphic hormonal response is reflected in a sex difference in Fos-like immunoreactivity (Fos-IR) in forebrain LHRH and non-LHRH neurons after mating. We used dual immunocytochemistry for Fos and LHRH to...

Progesterone is capable of facilitating or blocking the luteinizing hormone (LH) surge, depending on the timing of its administration. However, the precise targets of progesterone's actions are unknown. Since recent studies described the presence of a periventricular preoptic area (pePOA) neuron population afferent to LH-releasing hormone (LHRH) neurons that is co-activated to express c-Fos wit...

AIM To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. PATIENTS & METHODS A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual co...